Veranome's assay technologies allow targeted mapping of cellular spatial gene expressions with multiplexed in situ hybridization, as well as de novo profiling of cellular transcripts using in situ sequencing. The expanded assay portfolio, coupled with Veranome's imaging capabilities, allows customers to explore a range of applications, including characterization of cell and gene therapy methods and CRISPR screens, according to the companies.

Veranome will further develop these high-sensitivity assay chemistries to offer researchers the ability to profile archival formalin-fixed paraffin-embedded tissue blocks with the same spatial resolution as fresh frozen samples when analyzed on Veranome's spatial analyzer.

Veranome's broad portfolio aims to enable neuronal projection mapping, subtype classification, and elucidation of the functional organization of the brain. As part of the agreement, Veranome will collaborate with Cold Spring professor Dr. Anthony Zador, PhD, to accelerate these in situ spatial technologies, particularly within neuroscience.